Ginkgo Bioworks Holdings Inc.

Plus: Dadswell leaving Illumina as general counsel and updates from Eliem, Codexis, Oculis, Illumina, Eupraxia and PharmaJet

Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more 

The conversations the bill is sparking on supply chain diversification may have more impact than its prohibitions on federal contracting

With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the way

Plus: ALX hires Dillon and updates from Obsidian, YS and more

Survey of reliance on Chinese CDMOs, report from National Security Commission could convince lawmakers to modify anti-China bills

BIO’s new CEO lays out his vision for the trade organization, putting patients center stage

The U.S. can’t win by bashing China. It needs to focus on bolstering the industry

 Executive order targets bulk omics transfers to China

As WuXi stocks tumble, shares of ex-China CDMOs rise